EGFR and non-small cell lung carcinoma: An ongoing multicenter phase I trial is assessing the safety/tolerability and preliminary activity of patritumab deruxtecan in patients with advanced EGFR-mutated NSCLC who are pretreated with chemotherapy and develop disease progression on osimertinib or were T790M negative after disease progression while on erlotinib, gefitinib, or afatinib.67